Capricor Therapeutics shares rise 2% after FDA requests clinical trial data for deramiocel, a potential treatment for Duchenne muscular dystrophy, without requiring new studies.
Capricor's (CAPR) deramiocel cell therapy achieved significant skeletal and cardiac improvements in Duchenne muscular dystrophy patients, potentially reversing FDA rejection after July setback.
Capricor's DMD drug (HOPE-3 trial) got key FDA alignment, speeding up the approval process using existing files. Data is expected mid-Q4, with potential approval by mid-2026. Shares jumped 9%.
